AIGH Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

AIGH Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-162,547	Closed	-$2.3M	–	40
2024 Q1	$2.3M	Sell	162,547 -154,735	-49%	-$2.35M	0.69%	30
2023 Q4	$2.39M	Buy	317,282 +184,883	+140%	+$1.69M	0.94%	31
2023 Q3	$1.99M	Sell	132,399 -15,957	-11%	-$286K	0.94%	31
2023 Q2	$2.36M	Buy	148,356 +28,356	+24%	+$298K	0.96%	28
2023 Q1	$861K	Hold	120,000	–	–	0.32%	47
2022 Q4	$695K	Hold	120,000	–	–	0.23%	43
2022 Q3	$1.14M	Buy	+120,000	New	+$1.58M	0.35%	35

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

AIGH Capital Management's ADVM Position: Q2 2024 in Review

AIGH Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 162,547 shares — an estimated $2.3M sold.

AIGH Capital Management first reported a position in ADVM in Q3 2022 and held it in 7 quarters. The position peaked at $2.39M in Q4 2023. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

AIGH Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
AIGH Capital Management sold 162,547 Adverum Biotechnologies shares in Q2 2024, an estimated $2.3M.
AIGH Capital Management first reported a position in Adverum Biotechnologies in Q3 2022 and held it in 7 quarters.
AIGH Capital Management's Adverum Biotechnologies position peaked at $2.39M in Q4 2023.
68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on AIGH Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.